Bicycle Therapeutics Strengthens Board of Directors with New Appointments
BCYC(NASDAQ:BCYC) CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointments of Roger Dansey, M.D., and Hervé Hoppenot to the company’s Board of Directors. "We are thrilled to welcome Roger and Hervé to our Board of Directors as we make strong progress across our pipeline and anticipate numerous upcoming mi
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
BCYCCAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. “We continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation prec
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Raises Price Target to $17
BCYCRBC Capital Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $32
BCYCB. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $14
BCYCJMP Securities Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $22
BCYCA Glimpse Into The Expert Outlook On Bicycle Therapeutics Through 7 Analysts
BCYCNeedham Reiterates Buy on Bicycle Therapeutics, Maintains $29 Price Target
BCYCBarclays Maintains Overweight on Bicycle Therapeutics, Lowers Price Target to $15
BCYCBicycle Therapeutics Q1 EPS $(0.88) Misses $(0.86) Estimate, Collaboration Revenue $9.98M Beat $7.78M Estimate
BCYCBicycle Therapeutics Presents Addl Human Radiopharmaceutical Imaging Data For MT1-MMP At AACR Annual Meeting 2025
BCYCAnalyst Expectations For Bicycle Therapeutics's Future
BCYCNeedham Reiterates Buy on Bicycle Therapeutics, Maintains $30 Price Target
BCYCNeedham Reiterates Buy on Bicycle Therapeutics, Maintains $30 Price Target
BCYCBicycle Therapeutics Grants 73,700 Share Options To Eight New Employees Under 2024 Inducement Plan
BCYCEckert & Ziegler Enters Strategic Partnership With Bicycle Therapeutics For Radioisotope Supply And Contract Development And Manufacturing Of Bicycle Radio Conjugates
BCYCDeep Dive Into Bicycle Therapeutics Stock: Analyst Perspectives (9 Ratings)
BCYCCitizens Capital Markets Reiterates Market Outperform on Bicycle Therapeutics, Maintains $26 Price Target
BCYCHC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $33 Price Target
BCYCNeedham Reiterates Buy on Bicycle Therapeutics, Maintains $30 Price Target
BCYCBicycle Therapeutics Q4 2024 GAAP EPS $(0.75) Beats $(0.87) Estimate, Cash And Cash Equivalents Of $879.5M As Of December 31, 2024, Expected To Provide Financial Runway Into 2H 2027
BCYCHC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $33 Price Target
BCYCNeedham Reiterates Buy on Bicycle Therapeutics, Maintains $32 Price Target
BCYCBicycle Therapeutics Announced Updated Topline Phase 1 Combination Data For Zelenectide Pevedotin Plus Pembrolizumab In Previously Untreated (First-line) Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
BCYCRBC Capital Reiterates Outperform on Bicycle Therapeutics, Maintains $35 Price Target
BCYCHC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $55 Price Target
BCYCNeedham Reiterates Buy on Bicycle Therapeutics, Maintains $38 Price Target
BCYC6 Analysts Have This to Say About Bicycle Therapeutics
BCYCAnalysts have provided the following ratings for Bicycle Therapeutics (NASDAQ:BCYC) within the last quarter:
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $45
BCYC